Back to News
Market Impact: 0.4
Connect Biopharma Reports Positive Phase 2 Data For Rademikibart In Acute Asthma Exacerbations
Source: Nasdaq
Healthcare & BiotechProduct Launches
Connect Biopharma reported positive preliminary topline data from its global Phase 2 Seabreeze STAT Asthma study of rademikibart as an add-on treatment. The positive clinical readout is a meaningful development for the company’s inflammatory-disease pipeline and could support further advancement of the asthma candidate.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- SpaceX will try to put Starship in orbit for the first time on September 22
- A sharp stock market decline could lie around the corner, Wells Fargo warns
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio